Federal contract award
HHSO100201700012C
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541711 |
| PSC | 6505 — Drugs and Biologicals |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $236.3M |
| Current contract value | $236.3M |
| Potential contract value / ceiling | $291.4M |
| Start date | Sep 28, 2017 |
| Current end date | Sep 27, 2027 |
| Potential end date | Sep 27, 2027 |
| Latest award activity | Aug 5, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 11 of 11 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 5, 2026 | P00010 | $0 | MERCK - EBOLA ZAIRE VACCINE |
| Jun 27, 2024 | P00009 | $0 | MERCK - EBOLA ZAIRE VACCINE EXERCISE AND FUND OPTION 6 IN ORDER TO CONTINUE TO MEET THE REQUIREMENT OF MAINTAINING 1.13 MILLION DOSES OF ERVEBO. |
| Sep 21, 2023 | P00008 | $33.0M | MERCK - EBOLA ZAIRE VACCINE EXERCISE AND FUND OPTION 6 IN ORDER TO CONTINUE TO MEET THE REQUIREMENT OF MAINTAINING 1.13 MILLION DOSES OF ERVEBO. |
| Jan 18, 2022 | P00007 | $0 | MERCK - EBOLA ZAIRE VACCINE UPDATE SECTION J |
| Jun 7, 2021 | P00006 | $0 | MERCK - EBOLA ZAIRE VACCINE |
| Dec 8, 2020 | P00005 | $0 | MERCK - EBOLA ZAIRE VACCINE |
| Jun 24, 2020 | P00004 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE SECTION I.2. OF THE CONTRACT. |
| Apr 2, 2020 | P00003 | $132.0M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE FOLLOWING SECTIONS OF THE CONTRACT: SECTIONS B.2., B.3., B.5., C.1., F.1., G.1., G.2., AND J. ATTACHMENTS 1 AND 9. |
| Aug 14, 2019 | P00002 | $23.5M | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE FOLLOWING SECTIONS OF THE CONTRACT: SECTIONS B.2., B.5., C.1., G.1., AND J. |
| Feb 1, 2018 | 1 | $8.6M | IGF::OT::IGF |
| Sep 28, 2017 | 0 | $39.2M | IGF::OT::IGF |
Estimated positioning window
Oct 25, 2026 – Mar 27, 2027
80/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 80/100. Available recorded signals: 75 points.
- Contract end 2027-09-27 (337 days from calculation)
- +35 points
- 5 historical awards in this buyer and category group
- +15 points
- 11 recorded award transactions
- +10 points
- Latest award action: 2026-08-05
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.